Genesis Therapeutics, a Burlingame, CA-based company providing artificial intelligence (AI) technologies to create medicines for patients, announced an equity investment from NVIDIA’s NVentures.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate its AI platform, which is called GEMS (Genesis Exploration of Molecular Space).
Led by Evan Feinberg, Ph.D., Founder and CEO, Genesis Therapeutics is an AI-focused biotechnology company leveraging its generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space) for small molecule drug discovery, which integrates proprietary AI methods, including language models, diffusion models, and physical ML simulations, to generate and optimize molecules for complex targets.
Genesis is collaborating with NVIDIA to accelerate GEMS. The company will leverage NVIDIA’s expertise to make computation more efficient for several neural network architectures relevant to drug discovery. The collaboration will, among other areas, encompass optimizing equivariant neural networks, which are valuable for handling 3D geometric data such as protein and small molecule structures.
This investment is in addition to NVentures’ participation in the company’s $200M Series B financing in August 2023.
FinSMEs
14/11/2024